Latest Breaking News On - Invest new - Page 4 : vimarsana.com

Posted on 755 Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented preliminary data from the dose-escalation portion of its ARC-8 Phase 1/1b study, evaluating the safety and tolerability of AB680, the first small-molecule CD73 inhibitor to enter the clinic, in metastatic pancreatic cancer at the ASCO 2021 Virtual Gastrointestinal Cancers Symposium (ASCO GI). The ongoing, open-label, multicenter trial is a Phase 1/1b study evaluating the safety profile and clinical activity of AB680 in combination with nab-paclitaxel plus gemcitabine (NP/Gem) and zimberelimab, an anti-PD-1 antibody, as a first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).

United statesJohanna bendellKatherine bockSarah cannon research institute at tennessee oncologyDrug development unit nashvilleArcus biosciences incArcus biosciencesGastrointestinal cancers symposiumSafety resultsEfficacy resultsBill grossmanChief medical officerChief development officerSarah cannon research institutePrivate securities litigation reform actNat rev dis